No Data
No Data
Express News | Kyverna Therapeutics Files for Offering of up to $50 Mln Common Stock From Time to Time - SEC Filing
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Cuts Target Price to $4
Kyverna Therapeutics Price Target Cut to $4.00/Share From $6.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $4
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX) and Boundless Bio Inc. (BOLD)
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Cuts Target Price to $20